The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
Brian Huber
Advertisement
Brian Huber is vice-president of Therapeutic Areas, Drug Development, and Consulting at ICON.
Articles by Brian Huber
Advertisement
Latest Updated Articles
Challenges of Expanding CAR-T Cell Therapy into Solid TumorsPublished: May 3rd 2023 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
2
AAPS PharmSci 360 2025: Trends in Bioanalysis
3
PharmTech Weekly News Roundup – Week of November 3, 2025
4
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
5
